Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 1 · ActiveModality: orally bioavailable small molecule
Target PI3Kα (RAS-binding domain)
Partnerships Leidos / Lawrence Livermore (LLNS): in-licensed compound IP for PI3Kα breaker and KRAS programs (CRADAs + exclusive licenses); economics not disclosed
Indications
HER2+ breast cancer(Phase 1)
HR+/HER2- breast cancer(Phase 1)
KRAS mutant colorectal cancer(Phase 1)
KRAS mutant NSCLC(Phase 1)
Catalysts
— second half of 2026
Status note Lead candidate. BREAKER-101 Phase 1 enrolling; Phase 1a monotherapy dose escalation complete. Internal combination studies with BBO-8520 (opened Apr 2026) and BBO-11818 (opened Jul 2026). Preliminary data disclosed Jan 2026.
BBO-11818
Phase 1 · ActiveModality: orally bioavailable small molecule
Advanced KRAS-mutant pancreatic cancer (PDAC)(Phase 1)
Catalysts
— second half of 2026
Status note Pan-KRAS inhibitor. KONQUER-101 Phase 1 enrolling. FDA Fast Track granted Apr 20, 2026 for advanced KRAS-mutant PDAC. Internal combination study with BBO-10203 opened Jul 2026.
BBO-8520
Phase 1 · ActiveModality: orally bioavailable small molecule
Status note KRAS G12C inhibitor. ONKORAS-101 Phase 1a/1b enrolling (monotherapy and + pembrolizumab). FDA Fast Track for previously treated KRAS G12C-mutated metastatic NSCLC. New clinical data announced Jan 7, 2026. Internal combination study with BBO-10203 opened Apr 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.